Alchemia records loss despite positive trials

Company News

Alchemia Limited (ASX:ACL) has reported a net loss of $5.5 million for the first half of Fiscal 2014, up from $5.9 million for the same period last year.

A drop in total income for the period after the loss of an R&D tax incentive was highlighted by the company. Alchemia was also quick to highlight the encouraging results of ongoing clinical trials of advanced cancer drugs in the US, moving them closer to market.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.